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CREKA (Cys-Arg-Glu-Lys-Ala) is an important fibrin-homing pentapeptide that has 
been extensively demonstrated for diagnoses and therapies (e.g. image diagnosis of 
tumors and to inhibit tumor cell migration and invasion). Although CREKA-loaded 
nanoparticles (NPs) have received major interest as efficient biomedical systems for 
cancer diagnosis and treatment, almost no control on the peptide release has been 
achieved yet. Herein, we report the development of conductive polymer (CP) NPs as 
therapeutic CREKA carriers for controlled dose administration through electric stimuli. 
Furthermore, the study has been extended to CR(NMe)EKA (Scheme 1), a previously 
engineered CREKA analogue in which Glu was replaced by N-methyl-Glu for 
improvement of the peptide resistance against proteolysis, which is one of the major 
weaknesses of therapeutic peptide delivery, and for enhancement of the tumor homing 
capacity by over-stabilizing the bioactive conformation. Particularly, the present work 
has been focused on understanding the interactions between the newly designed 
nanoengineered materials and biological fluids and the achievement of a modulated 
peptide release by fine tuning the electrical stimuli. Two different types of stimuli were 
compared, chronoamperometry vs cyclic voltammetry, being the latter more effective.  
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The fibrin-homing pentapeptide Cys-Arg-Glu-Lys-Ala (CREKA; Scheme 1) 
interacts with fibrin clots and possesses favorable targeting ability to fibrin-fibronectin 
complexes in animal models of neoplasia, atherosclerosis and myocardial ischemica-
reperfusion.
1-3
 Since this peptide was discovered by in vivo phage display technique,
4
 it 
has been extensively utilized for the image diagnosis of tumors
5-9
 and to inhibit tumor 
cell migration and invasion.
10,11
 The fibrinogen released from tumor vessels is 
transformed into fibrin fibers by thrombin, which cleaves and removes fibrinopeptides. 
CREKA affects this process, catalyzing a very fast aggregation process, which results in 




Scheme 1. Chemical structure of CREKA (left) and CR(NMe)EKA (right). The 
chemical modification introduced in the Glu residue is marked in red.  
 
In order to improve the efficacy of CREKA-based diagnoses and therapies, most 
research has focused on loading this peptide in active targeting nanoparticles (NPs). For 
example, CREKA has been conjugated with polymer NPs
12-14
 [e.g. poly(ethylene 
glycol) (PEG), PEG-polylactic acid and polyamidoamine dendrimers], polymer-metal 
and polymer-metal oxide hybrid NPs
15,16
 [e.g. Au-PEG, Fe2O3-PEG and Fe3O4-
poly(lactic-co-glycolic acid)], and inorganic NPs
11,17-19
 (e.g. Fe2O3 and mesoporous 
silica) for targeted imaging of tumor cells and cancer therapies. Furthermore, this 





 The successful results obtained in all cases should be attributed to high 
stability of the bioactive conformation,
20
 which is preserved when the peptide is bound 
to NPs.
21,22 
In recent years, conducting polymers (CPs) have been considered as promising 
materials for the fabrication of electrically driven drug loading and delivery systems. 
Thus, CPs exhibit excellent redox properties that promote the uptake (oxidation) and 
expulsion (reduction) of charged drugs by applying an external electric field.
23-25
 
Because of the reversibility of their redox properties, CP-based systems provide not 
only on demand drug release, according to the clinical needs, but also repeatability of 
the delivered flux. Moreover, the potential of electro-responsive CP NPs has been 
recently extended to neutral drugs, such as curcumin, allowing their electrically pulsed 
linearly scalable, and on demand release.
26,27
 Notably, although CREKA has been 
incorporated to CP films to promote its ability to bind fibrin-fibronectin complexes,
28,29
 
this pentapeptide has never been loaded in CP NPs to modulate and program its 
controlled release with the applied stimulus. Although the utilization of CPs as drug 
delivery systems for humans is still in its early stages,
30
 in vivo assays using different 
types of electrochemical techniques for electrical stimulation have been successfully 
conducted.
31-33 
In an early work,
28
 CREKA was entrapped into films of poly(3,4-ethylenethiophene) 
(PEDOT), which is one of the most studied CPs because of its excellent properties (i.e. 
electrical conductivity, electrochemical activity and biocompatibility and great stability 
of the properties when exposed to air),
34-38
 using by applying different electrochemical 
procedures. The highest peptide concentration (i.e. one CREKA molecule per six repeat 
units) was obtained when PEDOT/CREKA films were prepared by chronoamperometry 
using a basic aqueous solution and adhered onto another previously generated PEDOT 
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film. Interestingly, PEDOT/CREKA films favored the cellular proliferation, which has 
been proved to be due to the binding of the peptide to the fibrin molecules from the 
serum used as a supplement in the culture media.
28
 More recently, PEDOT/CREKA 
films were found to affect the fibrin thrombin-catalyzed polymerization, inducing a very 
fast aggregation process.
29
 In absence of thrombin, PEDOT/CREKA induced a stepwise 
linear growth of fibrin particles.
29
  
In this work we are not focused on the therapeutic applications of CREKA, which 
have been extensively discussed,
1-19,28,29
 but on developing an electroactive bioplatform 
for storage and on-demand peptide release by electrical stimulation. For this purpose, 
PEDOT NPs obtained by emulsion polymerization have been loaded in situ with 
CREKA for electro-stimulated release. Furthermore, the study has been extended to 
CR(NMe)EKA (Scheme 1), a previously engineered CREKA analogue in which Glu 
was replaced by N-methyl-Glu for improvement of the peptide resistance against 
proteolysis and for enhancement of the tumor homing capacity by over-stabilizing the 
bioactive conformation.
11
 Results strongly support that PEDOT NPs are promising 
sensitive and stable bioplatforms for the storage and administration of controlled doses 
of CREKA and CR(NMe)EKA through electric stimuli. This approach is smart, facile 
and has excellent control for potential medical applications in which CREKA is gaining 
interest.  
 
RESULTS AND DISCUSSION 
Characterization of peptide-loaded NPs 
PEDOT NPs can be easily synthesized with the assistance of hard-templates
39-42
 that 
a priori are expected to give better control on the size and colloidal stability than soft 
templates, as for example surfactants.
43
 However, stable PEDOT NPs were recently 
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obtained using sodium dodecyl benzene sulfonate (SDBS) and iron (III) chloride as 
stabilizer and oxidant, respectively.
44,45
 In this work, PEDOT NPs have been prepared 
in water using ammonium persulfate (APS) as oxidizing agent and dodecyl benzene 
sulfonic acid (DBSA) as both stabilizer and doping agent, as reported in previous 
work.
26
 The two pentapeptides, CREKA and CR(NMe)EKA, were loaded in situ during 
the emulsion polymerization using the reaction conditions described in the Supporting 
Information. Hereafter, the resulting CREKA- and CR(NMe)EKA-loaded PEDOT NPs 
are denoted CREKA/PEDOT and CR(NMe)EKA/PEDOT, respectively. 
The morphology of unloaded and peptide-loaded NPs is compared in Figure 1, which 
includes representative scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM) micrographs, and atomic force microscopy (AFM). SEM 
micrographs (Figure 1a) show that the surface of the NPs is relatively smooth and 
uniform. Although the shape of unloaded NPs is relatively ill-defined, which has been 
attributed to the presence of surfactant left on the dried NPs, their sphericity increases 
when CREKA and CR(NMe)EKA are loaded. Thus, the drawback induced by the 
surfactant is partially compensated by the incorporation of charged peptides, which 
improves the spherical shape of the NPs. This feature is clearly evidenced when TEM 
micrographs recorded for isolated particles are compared with those obtained for 
CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs (Figure 1b). The distribution 
histograms (Figure 1c) obtained by measuring the diameter of such isolated particles 
(n= 100 in all cases) indicate that the size increases as follows: PEDOT NPs (35 ± 6 
nm) < CREKA/PEDOT NPs (43 ± 6 nm) < CR(NMe)EKA/PEDOT NPs (47 ± 9 nm). 
3D topographic AFM images (Figure 1d) of isolated NPs show a surface smoothness 
similar to that displayed by SEM micrographs. Besides, height profiles (Figure 1e) 
confirm that the size of the NPs increases upon the loading of the peptides, even though, 
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due to the influence of the tip, the diameters are less precise when determined by AFM 
than by SEM.  
 
Figure 1. Morphological characterization of PEDOT, CREKA/PEDOT and 
CR(NMe)EKA/PEDOT NPs: representative (a) SEM, (b) TEM and (c) AFM images of 
NPs aggregates. The size histograms (n= 100) displayed in (b) were derived from TEM 
images of isolated NPs. (d) Height profiles for the isolated NPs displayed in (d).  
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Figure 2a compares the FTIR spectra of DBSA, PEDOT NPs and the two 
peptide/PEDOT NPs. The DBSA spectrum shows strong absorbance bands at 2922 and 
2853 cm
-1
, which are assigned to the aliphatic –CH2 and –CH3 stretching vibration 
modes, respectively, and at 1646 cm
−1
 that are attributed to the C=C stretching vibration 
band of the phenyl side group. The spectrum recorded for PEDOT NPs display 
characteristic bands that correspond to the C=C stretching at 1650 and 1472 cm
-1
, the 
C–C of the quinoid thiophene ring at 1351 cm
-1
, the C–O–C vibrations at 1218 and 
1058 cm
−1
, and the stretch of the C–S bond in the thiophene ring at 836 and 683 cm
−1
. 
The presence of the shoulder at 1719 cm
−1
 has been attributed to the carbonyl group 
formed by the irreversible overoxidation of the thiophene ring in the conducting 
polymer (CP),
26,46,47
 which is induced by the APS. The loading of the peptides during 
the polymerization process did not affect the bands localization, even though an 
increase of the band at 1650 cm
-1
 was appreciated due to the presence of peptide bonds. 
The difference in absolute value between the bands at 1351 cm
-1
 (contribution from 
PEDOT) and 1650 cm
-1
 (contribution from both the peptide and PEDOT) divided 
between the maximum minus the minimum of the FTIR spectra expressed in percentage 
allowed us to compare the different samples. The difference between bands was much 
more pronounced for PEDOT NPs (98.5%) than for CREKA/PEDOT and 
CR(NMe)EDOT/PEDOT NPs (57.7% and 34.2%, respectively).  
To further confirm the successful loading of the peptides, CREKA/PEDOT and 
CR(NMe)EKA/PEDOT NPs were incubated in a Proteinase K solution at 37 ºC for 24 
h. Proteinase K is non-specific enzyme with broad cleavage specificity (i.e. it cleaves 
amide bonds adjacent to aliphatic, aromatic or hydrophobic residues).
48
 Figure 2b shows 
the FTIR spectra recorded for digested samples once they were centrifuged, washed 





was calculated as described above, increased again to 75.4% and 57.7% for 
CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs, respectively, demonstrating the 
loading of the peptides.  
 
Figure 2. FTIR spectra of DBSA, PEDOT NPs, CREKA/PEDOT NPs and 
CR(NMe)EKA/PEDOT NPs before (a) and after (b) Proteinase K digestion. (c) CD 
spectra of PEDOT, CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs dispersions. 
 
The structure of the loaded peptides was investigated by circular dichroism (CD). 
The spectrum recorded for PEDOT NPs (Figure 2c) did not show any secondary 
structure since no chiral compound was in the dispersion. In contrast, the CD spectra 
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obtained for both CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs show a minimum 
at 197 nm (Figure 2c), which is characteristic of a random coil secondary structure.
49
 
In order to examine the effect of the NPs on the stability of CR(NMe)EKA, which 
was engineered to be higher than that of CREKA without loss biological activitity,
11
 
unloaded (control) and loaded PEDOT NPs (1 mg/mL) where incubated with Proteinase 
K solution (1.8 U/mL) during 1, 24 and 96 h. Subsequently, the samples were frozen, 
lyophilized and re-solubilized with loading buffer to run a SDS-PAGE gel. As expected, 
no peptide band was observed for the control (Figure S1). However, a small band 
coming from the peptide signal was visualized below 6.5 KDa for CREKA/PEDOT and 
CR(NMe)EKA/PEDOT (Figure S1). The intensity of the band at each time point was 
compared to the band observed in loaded PEDOT NPs without being incubated with 
Proteinase K (Figure 3). As observed, the peptide signal lasted longer at higher intensity 
in the case of CR(NMe)EKA/PEDOT NPs, indicating that it needs longer time to be 
digested by Proteinase K and demonstrating that loaded CR(NMe)EKA is more stable 
than loaded CREKA. 
 
Figure 3. Intensity ratio (from SDS-PAGE gel in Figure S1) for CREKA/PEDOT and 
CR(NMe)EKA/PEDOT NPs before and after being incubated with proteinase K during 
different periods of time.  
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The peptide encapsulation efficiency was quantified by HPLC, subtracting the 
peptide remaining in the supernatant from the total amount of peptide added to the 
reaction solution. The loading capacity of PEDOT films prepared by anodic 
polymerization using CREKA and CR(NMe)EKA as dopant agents was found to be low 
(i.e. at a ratio of one peptide molecule every ~10 and ~15 polymer repeat units, 
respectively).
28,29
 However, the encapsulation efficiency of PEDOT NPs prepared by 
emulsion polymerization is significantly higher, as shown in Figure S2. Thus, the 
amount of encapsulated peptide detected by HPLC was 33.84.3 wt% for CREKA and 
43.22.9 wt% for CR(NMe)EKA (i.e. one peptide molecule every ~8 and ~6 polymer 
repeat units, respectively). The amount of encapsulated peptide is expected to be related 
with the size and amount of the NPs. As shown in Figure 1, the emulsion 
polymerization used in this work produced a large number of NPs with high surface / 
volume ratio, enhancing the peptide incorporation with respect to micrometric PEDOT 
films. 
All samples appeared to be spherical, highly monodisperse in size and stable in 
solution, which is due to the fact that the polymerization process employed in this work 
was designed to have control on both size and colloidal stability.
26,45
 A key criterion for 
the use of NPs in biomedical applications is the ability to maintain the size of the NPs or 
their aggregates as small as possible, preventing a blockage in the blood vessels or 
being eliminated by the body’s reticuloendothelial system (RES). More specifically, 
their size must be below 4 µm, the smallest diameter of human blood capillaries.
50
 
Figures 4a and 4b display the UV-vis spectra of CREKA/PEDOT and 
CR(NMe)EKA/PEDOT NPs, respectively, dispersed in phosphate buffer saline solution 
(PBS) at concentrations ranging from 5 to 50 µg/mL. As is shown by the linear increase 
of absorbance with the increasing peptide-NPs concentrations,
51
 both peptide-containing 
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NPs were perfectly dispersed in PBS without any macroscopic aggregates. The absence 
of aggregates is also evidenced in optical microscopy images deposited onto a cover 
glass (Figure 4c).  
The NPs stability was corroborated with dynamic light scattering (DLS) 
measurements over a period of two weeks (Figure S3). All NPs presented higher 
diameters than the ones seen by TEM due to the polymer hydration. Nevertheless, this 
diameter size and polydispersity was maintained during the study (two weeks), 
presenting some aggregation during the firsts four days for PEDOT and 
CR(NMe)EKA/PEDOT NPs. Interestingly, NPs with peptides showed smaller diameter 
than without them. This could mean that peptide presence increases the sample colloidal 
stability. CREKA/PEDOT NPs presented the smallest diameter and polydispersity. 
 
Hard protein corona on peptide-loaded NPs 
In order to achieve targeted delivery systems, it is necessary to evaluate the 
interaction between the proteins found on body fluids with the designed carriers. When 
materials are in contact with biological fluids they adsorb different biomolecules due to 
their high surface free energy. Therefore, the hard protein corona, which is a tightly 
bound monolayer of proteins with high affinity for the NPs surface, will define the 
biological identity of engineered NPs, influencing cytotoxicity, targeting, body 
distribution and endocytosis into specific cells.
52
 Although recent advances on this field 
have been done, not much attention has been focused on CP···protein interactions. For 
that reason, in this section we explore this field using fetal bovine serum (FBS) as a 
representative mixture of serum proteins. The discussion of this section is focused on 
the formation of the protein corona on PEDOT, CREKA/PEDOT and 
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CR(NMe)EKA/PEDOT NPs rather than on the detailed composition and properties of 
such corona. 
 
Figure 4. UV-Vis spectra of (a) CREKA/PEDOT and (b) CR(NMe)EKA/PEDOT NPs 
at different concentrations (from 5 to 50 g/mL). (c) Optical Image of CREKA/PEDOT 
NPs deposited onto a cover glass. (d) Aqueous electrophoretic curves recorded for 
PEDOT, CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs dispersed in 1 mM KCl at 
different pHs. (e) SDS-PAGE analysis of the pattern of FBS proteins adsorbed on 




The variation of the surface Z-potential with the pH was determined for the NPs by 
aqueous electrophoresis since the charge at the slipping plane is expected to influence 
protein absorption. Figure 4d shows the electrophoretic curves obtained for re-dispersed 
PEDOT, CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs in the presence of 1 mM 
KCl as background electrolyte. The isoelectric point (IP) point of PEDOT NPs was ~4 
since the anionic surfactant (pKa 2.8) is adsorbed at the NPs surface, balancing the 
cationic charge of the PEDOT backbone. Instead, the IP of CREKA/PEDOT and 
CR(NMe)EKA/PEDOT NPs is 5.5 and 6.5, respectively, being closer to that of the 
peptides (IP: 8.5). Thus, Arg and Lys residues display positive charges while Glu 
(CREKA) and N-methyl-Glu (CR(NMe)EKA) residues impart a negative charge.  
Subsequently, unloaded and peptide-loaded NPs were incubated with FBS at 37 ºC 
and then washed three-times in order to get rid of the proteins weakly bound to the 
surface. According to previous studies, which claim that the protein corona is formed 
over a period of 1 h, the incubation time was set at 1 h.
53,54
 Afterwards, SDS-PAGE gels 
were run (Figure 4e), confirming the formation of the hard corona. The coronal 
composition was similar for the three types of NPs, BSA being the most prominent 
protein on the corona of the three species. However, the quantity of bound proteins was 
higher for CR(NMe)EKA/PEDOT NPs, even though in that case the size of the NP is 
slightly bigger (i.e. lower surface / volute ratio), as shown in Figure 1. The amount of 
adsorbed proteins increases with the size of the molecules, the charge and the 
hydrophobicity of the particle surface. In addition, hydrophobic interactions have an 
important effect on protein adsorption, so that dehydration of hydrophobic areas 
produces an entropy gain that in turn could facilitate protein adsorption.  
In relation with protein adhesion capabilities, isolated and known mixtures of 
different proteins were investigated at different pHs (i.e. acid, neutral and basic) for the 
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three types of NPs. The chosen proteins were lysozyme (LYS; IP= 11.3), bovine serum 
albumin (BSA; IP= 4.7) and fibrinogen (Fg; IP= 5.5). Gel electrophoresis, which proves 
the size and charge of a species, simultaneously, and Z-potential of the washed NPs 
after incubation with LYS, BSA and Fg for 1 h at 37 ºC are displayed in Figure 5.  
 
Figure 5. SDS-PAGE (left) and Zeta potential (right) of the PEDOT, CREKA/PEDOT 





Importantly, protein···NP complexes were only formed when proteins were 
positively charged (i.e. LYS at the three studied pHs and Fg at pH 5). In Figure 4 it is 
possible to detect BSA bounded to NPs, however, this is just an indicative that when 
many proteins are present they can bound to each other generating protein multilayers. 
For instance, BSA can be bound to positively charged proteins bound to NPs surface. 
Comparison of the Z-potential of the NPs before (Figure 4d) and after protein 
incubation (Figure 5) reflects a change in the effective electric charge of peptide loaded 
NPs surface, which becomes less negative than for unloaded NPs when positively 
charged proteins are bound. Similar studies were conducted using equimolar LYS:Fg 
and LYS:BSA mixtures. As shown in Figure S4, after incubation the binding on the 
NPs was greater for Fg than for BSA. As it was expected, this effect was more 
pronounced for the peptide-loaded NPs than for the unloaded ones due to the specific 




Cytotoxicity and cellular-uptake of peptide-loaded NPs 
Previous studies in vitro and in vivo have demonstrated PEDOT as a biocompatible 
material.
38,55-57
 Also, therapeutic doses of CREKA and CR(NMe)EKA were 
investigated in vivo.
11
 In this work, the cytotoxicity of DBSA, PEDOT NPs, 
CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs was tested in four different cell 
lines: metastatic prostate epithelial cells (PC3); Rattus norvegicus kidney normal cells 
(NRK); Madin-Darby canine kidney (MDCK) cells transfected with the cDNA of 
human 2,6-sialtransferase (SIAT); normal prostate epithelium immortalized with SV40 
(PNT2). The viability of PC3 cells (highest toxicity among the studied cell lines), as 
determined by the MTT assay, after 24 h post-treatment is compared in Figure 6a for 
the four materials under study and the corresponding control (cells incubated in the 
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wells without NPs), while results obtained for NRK, MDCK-SIAT and PNT2 cell lines 
are shown in Figure S5.  
 
Figure 6. (a) Cytotoxicity studies of PEDOT, CREKA/PEDOT and 
CR(NMe)EKA/PEDOT NPs on PC3 cells for 24 h. For the sake of completeness, 
independent cytotoxicity studies were also conducted for DBSA. Values are the mean of 
3 samples and bars indicate their standard deviation. Results for NRK, MDCK-SIAT 
and PNT2 cells are displayed in Figure S6. (b) TEM images of PC3 cells incubated 
without NPs (control), PEDOT NPs (blank), CREKA/PEDOT NPs and 
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CR(NMe)EKA/PEDOT-CR(NMe)EKA NPs for 24 h (25 mg/mL). Red arrows indicate 
the NPs. (N: nucleus; M: mitochondria; V: vacuoles; E: endosome; and PM: plasma 
membrane). 
 
Results indicate that the PEDOT NPs do not exert toxicity on PC3 cells, even at very 
high concentrations. This has been attributed to the elimination of the DBSA, which 
was used as stabilizer and dopant agent in the emulsion polymerization process, during 
the successive washing steps applied after the synthesis of the NPs. Indeed, although the 
toxic effect of DBSA on PC3 cells starts at 6 g/L, this concentration is around 533 
times lower than the one used for the synthesis of PEDOT NPs. Cell viability profiles 
obtained for NRK, MDCK-SIAT and PNT2 cells provided similar observations with 
respect to the potential role of PEDOT NPs to act as non-toxic drug carriers and the 
toxicity of DBSA, even though the latter showed cell line dependence. Thus, the 
cytotoxicity of DBSA against NRK, MCDK-SIAT and PNT2 cells was 16, 8 and 2 
times less severe than its cytotoxicity against PC3 cells. 
Peptide-loaded NPs present some differences with respect to the harmless unloaded 
PEDOT NPs. In general, cell viabilities in PC3 (Figure 6a) are lower for 
CREKA/PEDOT and CR(NMe)DOT/PEDOT than for PEDOT. However, no significant 
cell death was detected for peptide-loaded NPs as compared to nontoxic unloaded 
PEDOT until a high NPs concentration was tested (i.e. 500 g/L). Instead, cell 
viabilities in NRK, MDCK-SIAT and PNT2 (Figure S5) are comparable (NRK) or even 
higher (MCDK-SIAT and PNT2) for peptide-loaded NPs than for unloaded NPs, 
suggesting that the toxicity effects of CREKA and CR(NMe)EKA depends significantly 
on the cell line. Differences between the response of PC3 and the other three cell lines 
against the peptide concentration might be due to the formation Zn–S interactions 
involving the sulphur atom of Cys. Although the redox metabolism associated with Zn–
19 
 
S(Cys) complexes is involved in protein structure regulation,
58
 alterations in the Zn
2+
 
regulation cause stress, even inducing cellular apoptosis. Considering that proliferation 




 it can be 
hypothesized that Zn-chelation through the formation Zn–S(Cys) complexes explains 
the effects of the studied peptides in this cell line.  
In order to provide a more comprehensive understanding of the response of cells to 
peptide-loaded NPs exposure, transmission electron microscopy (TEM) was used to 
study the internalization of the NPs by PC3 cells. This cell line was selected because of 
its sensitivity to the toxicity effects of CREKA and CR(NMe)EKA. Figure 6b shows 
representative TEM images of PC3 cells incubated in absence of NPs (control) and with 
PEDOT (blank), CREKA/PEDOT and CR(NMe)EDOT/PEDOT NPs for 24 h. 
Additional TEM micrographs for CREKA/PEDOT and CR(NMe)EDOT/PEDOT are 
provided in Figure S6. The three types of examined NPs were internalized in PC3 cells, 
even though the uptake process did not induce significant changes in the cell 
morphology. NPs enter the cell as individual or groups of some few particles and, upon 
entering the cytoplasm, they form vesicular endosome-like structures. This distribution 
of the internalized NPs suggests that NPs were taken up by PC3 cells through 
endocytosis (isolated NPs) and phagocytosis (groups of NPs), which is the uptake for 
particulates larger than 0.5 m. Both processes start through the binding of NPs to 
specific cell surface proteins and receptors. 
 
Electro-stimulated peptide release 
Before conducting electrically stimulated peptide delivery assays, the influence of 
the CREKA and CR(NMe)EKA on the electrochemical activity of PEDOT NPs was 
examined by cyclic voltammetry. Figure 7a shows the voltammograms recorded for 
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glassy carbon electrodes coated with PEDOT, CREKA/PEDOT and 
CR(NMe)EKA/PEDOT NPs at different scan rates (c) in PBS 1 pH 7.4. As expected, 
in all cases the current intensity increases with c. Moreover, the peptides do not have a 
significant influence in the electrochemical activity of the CP NPs, the area and shape of 
the voltammograms being similar for the three systems under study, independently of c.  
 
Figure 7. (a) Cyclic voltammograms recorded for glassy carbon electrodes coated with 
PEDOT, CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs at scan rates from 10 to 200 
mV/s in PBS 1. (b) Variation of the intensity at the reversal potential (Irp) versus the 
scan rate (c) and square root of the scan rate (c
1/2
) for PEDOT, CREKA/PEDOT and 
CR(NMe)EKA/PEDOT NPs. (c) Logarithm of the intensity at the reversal potential 
(Log Irp) versus the logarithm of the scan rate (Log c) for CREKA/PEDOT and 
CR(NMe)EKA/PEDOT NPs.  
 
The anodic peak (oxidation process) at a potential higher than the reversal potential 
and the cathodic peak (reduction process) at 0.14 V are well defined in all cases, the 
corresponding peak current intensity increasing with c. Figure 7b compares the 





) for unloaded and peptide-loaded PEDOT NPs (left and right, respectively). For 
unloaded PEDOT NPs, the highest linearity was obtained for the variation of the 
intensity against c (R
2
= 0.9841), indicating that this system is predominantly controlled 
by absorption processes. Instead, the linearity of Irp and c
1/2
 was higher for 
CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs, which indicates that peptide-loading 
transforms PEDOT NPs into predominantly diffusion controlled current systems. 
Indeed, although the plot of the logarithm of Irp versus the logarithm of c retains the 
linear behavior for CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs (Figure 7c), the 
obtained slopes (0.62 and 0.69, respectively) differ from the theoretical value of 0.5 for 
an ideal diffusion controlled system,
60
 evidencing the participation of absorption 
processes as in unloaded NPs.  
The release of the peptides from loaded NPs was quantified by HPLC at 220 nm in 
all cases. The released amount of peptide from CREKA/PEDOT NPs triggered by 
cyclic voltammetry (CV) stimuli in PBS is displayed in Figure 8a. As a control, HPLC 
chromatograms were taken from CREKA/PEDOT NPs dipped in PBS to which no 
electrical stimulus was applied. As expected, there was no significant release of 
CREKA by diffusion after 24 h from those control samples, evidencing that 
CREKA/PEDOT is an electrically regulated release system. From the initially loaded 
peptide, 14.4%  7.6% and 35.0%6.6% were released after 50 and 100 CV cycles, 
respectively, at a scan rate of 100 mV/s. This represents a release of 0.3% per CV 
cycle, which could allow an exhaustive control of the dosage. 
The fundamental principle behind this release is based on the movement of ions in or 

























The mechanism expressed in Eqn (1), which is sketched in Scheme 2 for 
CREKA/PEDOT NPs, shows that, initially, the peptide remains adsorbed onto the NPs 
through attractive electrostatic interactions between the positively charged residues of 
the (Arg and Lys) and the dopant DBSA
–
 anions.  After the injection of electrons during 
the cathodic scan, the doping level (i.e. the amount of positive charge distributed along 
PEDOT chains) decreases and, therefore, some dopant anions are expelled from the NPs 
surface. This change in the oxidation level of the CP and the consequent reduction of 
DBSA
–
 anions affects the electrostatic interactions with peptide, which is partially 
released to the medium.   
 
Scheme 2. Sketch illustrating the mechanism of peptide release from CREKA/PEDOT 
NPs. The change in the intensity of the blue color of the NPs refer to a reduction of the 
doping level. The reduction of the thickness representing adsorbed DBSA
–
 and peptide 
molecules indicate the release of these molecules associated to the decrease of doping 
level. 
 
In CV assays the potential was swept from a negative potential (-0.40 V) to a 
positive potential (+0.80 V) changing the oxidation state of the CP NPs supported onto 
stainless steel, as is reflected by the recorded voltammograms (Figure 8a). The 
reduction of the PEDOT NPs causes the release the peptide, while ions from the PBS 





Figure 8. (a) Peptide (in %) released from CREKA/PEDOT NPs by applying 50 and 
100 CV cycles at 100 mV/s (left) using a potential window between -0.40 V (initial and 
final potential) and 0.80 V (reversal potential) and recorded voltammograms (right) for 
stainless steel coated with CREKA/PEDOT NPs. (b) Peptide (in %) released from 
CREKA/PEDOT NPs by applying a potential of +0.50 V and -0.50 V during 180 s (left) 
and recorded chronoamperograms (right) for stainless steel electrode coated with 
CREKA/PEDOT NPs. 
 
Additional studies were also conducted to monitor the CREKA release from loaded 
NPs by chronoamperometry (CA) applying voltages of +0.50 and -0.50 V for 180 s. As 
shown in Figure 8b, the application of the positive potential resulted in a very low 
release (7.3%  3.0%) after such period of time. This expected result has been attributed 
to the structural damages caused by the overoxidation of the CP, which induces the 
release of a small fraction of peptide. This phenomenon is reflected in the recorded 
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chronoamperograms, which display a progressive increment in the current intensity with 
time. Instead, the application of a negative potential causes the reduction of the CP and 
the release of 14.9%  2.8% of the loaded peptide. The latter value is significantly lower 
than that obtained using CV, indicating that CA is not the appropriate technique to 
regulate the pentapeptide release by electrical stimulation. 
As it was expected, results for CR(NMe)EKA/PEDOT NPs, which are shown in 
Figure S7, are consistent with those discussed for CREKA/PEDOT. Thus, the peptide 
release was significantly higher by CV than by CA, reaching a total amount of 16.1%  
6.2% and 37.8%6.3% after 50 and 100 CV cycles, respectively.  
In order to explore a possible approach to inject CREKA/PEDOT and 
CR(NMe)EDOT/PEDOT NPs in vivo; chitosan (CHI) hydrogels containing the NPs 
were engineered and analyzed by CV. It is worth noting that this system could allow the 
injection of the NPs through a 3D network of a biocompatible polymer rather than 
attached to stainless steel electrodes. A similar approach was shown by Ge et al.,
32
 who 
loaded polypyrrole NPs in a temperature-sensitive hydrogel that was subsequently used 
for in vivo controlled drug delivery. In the present work, 10 µL of CHI hydrogel alone 
and CHI loaded with PEDOT, CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs (CHI-
PEDOT, CHI-CREKA/PEDOT and CHI-CR(NMe)EDOT, respectively) were dropped 
on screen printed electrodes (Figure 9a). Cyclic voltammograms, which were recorded 
at 100 mV/s from -0.4V to 0.8V, are displayed in Figure 9b and are similar to the ones 
obtained using NPs directly supported onto solid electrodes (Figure 7a). Indeed, current 
densities are higher for CP NPs loaded into hydrogels than for CP NPs supported on 
solid electrodes. This feature indicates that CHI hydrogels allow a more efficient 
electron transfer between the electrolytic solution and the CP NPs than solid electrodes, 
which has been attributed to the greater accessibility of the NPs loaded into the 
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hydrogel. Overall, these results demonstrate that the combination of CP NPs and CHI 
hydrogels could be used to deliver therapeutic peptides. 
 
Figure 9. (a) Photographs of unloaded CHI hydrogel and loaded CHI-PEDOT, CHI-
CREKA/PEDOT and CHI-CR(NMe)EKA/PEDOT hydrogels drop-casted onto screen 
printed electrodes. (b) Cyclic voltammograms of CHI alone, CHI-PEDOT, CHI-
CREKA/PEDOT and CHI-CR(NMe)EKA/PEDOT in PBS 1, pH 7.4. 
 
Considering previous in vivo studies using electroresponsive drug-loaded NPs 
embedded in biodegradable hydrogels,
32
 which showed the absence of fibrous tissue 
encapsulation and excellent biocompatibility, and the benefits observed in this work for 
PEDOT NPs loaded with CREKA and CR(NMe)EKA, our next step for the biomedical 
application of these CREKA/PEDOT and CR(NMe)EKA/PEDOT NPs as drug delivery 
systems will be the incorporation of the biodegradable groups. More specifically, NPs 
will be prepared using macromonomers formed by small PEDOT tracts ended with 
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enzymatically cleavable or hydrolysable linkages (e.g. esters).
61
 This strategy has been 





CREKA and CR(NMe)EKA can be easily incorporated onto PEDOT NPs and 
released in a controlled manner depending on the applied stimuli. Analyses of the 
interaction between PEDOT NPs and biological fluids indicates that the protein corona 
is mainly governed by electrostatic forces between the NP surface and the protein 
charge, which is completely dependent on the solution pH. Although the therapeutic 
applications of CREKA are not within the scope of this work because they have been 
extensively demonstrated,
1-19,28,29
 our results evidence that PC3 cells are more 
susceptible to CREKA and CR(NMe)KA loaded particles than MCDK-SIAT, NRK and 
PNT2 cells. The release of CREKA and CR(NMe)EKA can be fine-tuned by 
modulating the strength of peptide···CP interactions, which becomes weaker when 
polymer chains are reduced and oxidized applying an external voltage. Two different 
types of electrical stimuli have been compared: fixed voltage vs voltage linear ramp, 
being the latter much more effective than the former. Peptide 0.3% release was 
achieved every CV cycle.  
It should be mentioned that PEDOT, as many other CPs, is not itself inherently 
biodegradable, however, resorbable versions of this CP are currently under development 
by adding enzymatically cleavable or hydrolysable linkages as connections between 
small segment with electronic conductivity. As loaded PEDOT NPs have been revealed 
as a promising complement for CREKA and CR(NMe)EKA-based therapeutics, we are 
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currently working in development of biodegradable PEDOT-based NPs for this 
biomedical application.  
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